Cibus, Inc. (CBUS) has a MoatMap StockRank of 1/100 based on Quality (10/100), Value (35/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. Agricultural gene-editing firm with high cash burn and pre-revenue characteristics, failing our quality compounder filter.
Cibus, Inc. develops and commercializes advanced non-GMO and gene-edited plant traits for agricultural applications, focusing on improving crop yields and sustainability. The company leverages its proprietary Rapid Trait Development System (RTDS) platform, allowing precise genetic modifications without introducing foreign DNA. Cibus is a pioneer in sustainable agricultural biotechnology, offering an alternative to traditional GMOs.
| Price | $1.23 |
| Market Cap | $117M |
| P/E (Forward) | -2.22 |
| Price/Book | 3.48 |
| Return on Equity | -221.0% |
| Return on Invested Capital | -33.6% |
| Debt/Equity | 1227.56 |
| Gross Margin | 100.0% |
| Operating Margin | -1273.3% |
| Revenue Growth | -12.8% |
| Free Cash Flow | $-52M |
Cibus, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).